Safety and efficacy of intracameral moxifloxacin injection for prophylaxis of endophthalmitis after phacoemulsification by Vieira, Ibraim Viana et al.
Original article 
165Arq Bras Oftalmol. 2017;80(3):165-7http://dx.doi.org/10.5935/0004-2749.20170040
INTRODUCTION
Although rare, postoperative endophthalmitis is one of the most 
feared complications of cataract surgery. It may significantly com-
promise visual function and even the anatomical integrity of the eye. 
At the beginning of the twentieth century, before the development 
of antibiotics, the incidence of postoperative ocular infection was 
approximately 1%-5%(1); nowadays, the percentage of endophthal-
mitis after intraocular surgery has been lowered to 0.04% to 0.2%(2-4). 
Despite the significant reduction in recent years, considering the 
millions of people who undergo cataract surgery each year, posto-
perative endophthalmitis still poses a significant public health issue, 
which has been addressed in several studies(5,6). The preoperative use 
of povidone-iodine is an effective method to prevent endophthal-
mitis(5). However, administration of systemic or periocular injections 
of antibiotics is controversial and there is insufficient evidence to 
support its use(6).
In the last decade, several studies have suggested that the in-
tracameral (IC) use of antibiotics may reduce endophthalmitis risk(7,8). 
The administration of antibiotics in the anterior chamber after 
surgery is theoretically the most direct method for prophylaxis. The 
dissemination of this practice started after a multicenter, prospective, 
randomized controlled trial performed by the European Society of 
Cataract and Refractive Surgeons (ESCRS) showed a 4.92 increase in 
the risk of total postoperative endophthalmitis in the group that did 
not receive cefuroxime in the anterior chamber(7). 
Since then, studies have tested the safety and efficacy of IC in-
jection of other antibiotics, such as moxifloxacin(9-11). This antibiotic 
has been widely used in the anterior segment and, due to the lack 
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ABSTRACT
Purpose: To evaluate the safety and efficacy of 0.05 mL intracameral injection 
of moxifloxacin in patients who underwent phacoemulsification and intraocular 
lens (IOL) implant. 
Methods: Retrospective study comprising patients who underwent phacoemul-
sification and IOL implant between January 2009 and December 2013. Patients 
were divided into two groups. Group A followed standard endophthalmitis 
prevention protocol and group B followed the same protocol plus intracameral 
injection of 0.05 mL of moxifloxacin hydrochloride at 5.45 mg/mL, immediately 
after IOL implant. 
Results: Medical records from 7,195 eyes of 3,751 patients (median age: 67.8 ± 
8.96, range: 48-83 years, 53.8% female) were evaluated. Group A included 3,515 
eyes of 1,838 patients and group B included 3,680 eyes of 1,913 patients. The 
incidence of endophthalmitis in group A was 0.22% (8:3,515 eyes) and in group B 
was 0.03% (1:3,680 eyes, p=0.0198, Fischer’s exact test). No toxicity or inflammation 
related to the use of moxifloxacin was observed. 
Conclusions: There was a 7.3-fold lower ratio of endophthalmitis in the group 
that received moxifloxacin intracameral injection. This study provides further 
evidence that moxifloxacin is an effective intracameral prophylactic antibiotic.
Keywords: Endophthalmitis; Cataract; Phacoemulsification; Anti-bacterial agents; 
Injections; Antibiotic prophylaxis
RESUMO
Objetivo: Avaliar a segurança e a eficácia da injeção intracameral de 0,05 mL de 
moxifloxacina em pacientes que realizaram facoemulsificação e implante de lente 
intraocular. 
Métodos: Estudo retrospectivo envolvendo pacientes submetidos a facoemulsifi-
cação e implante de lente intraocular entre janeiro de 2009 a dezembro de 2013. 
Os pacientes foram divididos em dois grupos. O grupo A seguiu o protocolo padrão 
de prevenção de endoftalmite e o grupo B seguiu o mesmo protocolo associado 
à injeção intracameral de 0,05 mL de cloridrato de moxifloxacino a 5,45 mg/mL, 
imediatamente após o implante de lentes intra-oculares (LIO). 
Resultados: Foram avaliados registros clínicos de 7.195 olhos de 3.751 pacientes 
(mediana de idade de 67,8 ± 8,96, faixa de 48-83 anos, 53,8% de mulheres). O grupo A 
incluiu 3.515 olhos de 1.838 pacientes e o grupo B incluiu 3.680 olhos de 1.913 pacientes. 
A incidência de endoftalmite no grupo A foi de 0,22% (8:3.515 olhos) e no grupo B de 
0,03% (1:3.680 olhos, p=0,0198, teste exato de Fischer). Não foi observada toxicidade 
ou inflamação relacionada com o uso de moxifloxacino intracameral. 
Conclusões: Houve uma proporção 7,3 vezes menor de endoftalmite no grupo que 
recebeu injeção de moxifloxacino. Este estudo fornece mais evidências que o moxiflo-
xacino intracameral é um antibiótico profilático intracameral eficaz.
Descritores: Endoftalmite; Catarata; Facoemulsificação; Antibacterianos; Injeções; 
Antibioticoprofilaxia
Safety and efficacy of intracameral moxifloxacin injection for prophylaxiS of endophthalmitiS after phacoemulSification
166 Arq Bras Oftalmol. 2017;80(3):165-7
of preservatives in its commercial eye drop formula, it has been 
used intracamerally with no reports of ocular toxicity(12). The choice 
of moxifloxacin instead of cefuroxime may be based on the rapid 
medication turnover after surgery, lending favor to moxifloxacin 
(which is concentration-dependent) over cefuroxime (which is 
time-dependent)(13).
Considering the reports of reduction in endophthalmitis with 
IC antibiotic injection and the absence of evidence or consensus 
as to which antibiotic is superior in preventing endophthalmitis(14), 
our service decided to adopt IC injection of commercially-available 
moxifloxacin at the end of phacoemulsification starting June 06, 
2011. In view of the perceivable reduction in endophthalmitis after 
the adoption of IC antibiotic prophylaxis and the absence of similar 
studies in Brazil, we decided to retrospectively evaluate our data, 
which is the focus of the current study.
METHODS
This is a retrospective clinical registry-based study. Its protocol 
was conducted according to the principles described in the declara-
tion of Helsinki. All data were collected, manipulated, and analyzed 
without personal identification of patients.
The study population comprised all patients ≥18 years old who 
underwent phacoemulsification with intraocular implant between 
January 2009 and December 2013 at a private ophthalmologic hos-
pital in Brasilia, Brazil. Patients were divided into two groups: group 
A received one drop of 5% povidone-iodine (Ophthalmos, São Paulo, 
Brazil) 15 minutes before surgery and postoperative antibiotics 
eye drops 4 times per day for 10 days; group B received the same 
prophylaxis for endophthalmitis as group A, plus an IC injection of 
0.05 mL of commercially available moxifloxacin hydrochloride at 
5.45 mg/mL (Vigamox®, Alcon Laboratories, Inc., Fort Worth, TX) 
immediately after IOL implant. 
All patients had scheduled consultations at one, seven, and thirty 
days after surgery, and were instructed to return to the clinic in case 
of alarming signals between follow-up evaluations.
Postoperative endophthalmitis was defined as inflammation in 
the anterior chamber or vitreous cavity occurring within 6 weeks 
after surgery that responded to intravitreal antibiotics or presented 
positive cultures. The data was analyzed by descriptive statistics and 
Fisher’s exact test to compare groups, statistical significance level 
(p<0.05).
RESULTS
A total of 7,195 eyes of 3,751 patients were retrospectively evalua-
ted (median age: 67.8 ± 8.96 years, range: 48-83 years, 53.8% female). 
Group A included 3,515 eyes of 1,838 patients (median age: 68.1 ± 8.92 
years, range: 52-83 years, 54.4% female), and group B included 3,680 
eyes of 1,913 patients (median age: 67.7 ± 9.03 years, range: 48-82 
years, 53.5% female), as shown in table 1. 
The incidence of endophthalmitis in group A was 0.22% (8:3,515 
eyes) and in group B was 0.03% (1:3,680 eyes, p=0.0198, Fisher’s exact 
test).
DISCUSSION
Gram-positive bacteria are the most common cause of posto-
perative endophthalmitis in the West(3). However, the prevalence of 
certain causative agents may vary according to geographic region. 
A study conducted in Brazil pointed to coagulase negative agents 
such as Staphylococci and Streptococcus viridans as the primary pa-
thogens in a university-based hospital; however, the wide spectrum 
of detected microorganisms also includes gram-negative bacteria 
such as Pseudomonas aeruginosa and Haemophilus sp. As such, pro-
phylactic antibiotics are usually chosen based on their low toxicity 
and large spectrum.
Despite many studies pointing to a reduction in endophthal-
mitis cases after IC administration following cataract surgery, many 
surgeons justify not introducing this practice into their routine due 
to risks associated with the procedure, such as dilution errors, conta-
mination, and drug toxicity(11). Their concerns are justifiable; due to 
the absence of a commercial formula, IC antibiotics must be prepared 
in a sterile environment and diluted by the surgeon. Dilution errors 
with cefuroxime have been documented as a possible cause for pos-
toperative toxic anterior segment syndrome and even more severe 
adverse effects such as macular infarction(15). Toxicity may result not 
only from the drug itself but also from preservatives or abnormal 
osmolality or pH(3).
Moxifloxacin (Vigamox®, Alcon Laboratories, Inc., Fort Worth, TX) 
is preservative-free and isotonic, with a pH of 6.8 and an osmolality of 
approximately 290 mOsm/kg(13) and has been used as an IC prophyla-
xis(11,12,14). These values are very similar to those of the aqueous humor 
(pH=7.4, osmolality=305 mOsm/kg)(13), and may help to explain why 
the use of IC Vigamox has not been associated with ocular toxicity at 
full strength or with a 50:50 dilution in balanced salt solutions.
Moxifloxacin is a fourth-generation quinolone that exerts its 
antibacterial effect by preventing bacterial DNA from unwinding 
and duplicating, mainly acting on DNA gyrases and topoisomerases. 
Moxifloxacin provides an improved activity against gram-positive 
bacteria and atypical pathogens than did earlier fluoroquinolone 
agents such as levofloxacin, ofloxacin, and ciprofloxacin, while main-
taining good activity against gram-negative bacteria. Furthermore, 
it presents high potency, better tissue penetration, and delayed 
antibiotic resistance(10,16).
Different methods of IC use for commercially available moxifloxa-
cin have been proposed, such as flushing the anterior chamber with 
2 to 3 mL of diluted solution(11) or the use of a relatively small volume 
(0.05 to 0.2 mL) of highly concentrated solution (undiluted or diluted 
up to 10-fold) at the end of surgery(13). Considering that this antibiotic 
has not demonstrated toxicity to endothelial cells in concentrations 
as high as 500 µg/mL(10), and given that that its mechanism of action 
is concentration-dependent, we preferred to perform a 0.05 mL IC 
injection of undiluted moxifloxacin.
We found a 7.3-fold lower ratio of endophthalmitis after cataract 
surgery in the group that received moxifloxacin during surgery. 
Although this decrease is higher than other comparable studies, it 
may be explained by a slightly higher rate of endophthalmitis prior 
to the adoption of IC injection. A previous study demonstrated that 
the IC use of commercially available moxifloxacin eye drops led 
to an endophthalmitis rate of 1:6,265, which is a 3-fold decrease 
compared with the group that did not receive the antibiotic(11). In 
a recently published study from India, a 4-fold reduction in endo-
phthalmitis was observed in patients that underwent small-incision 
cataract surgery and received IC injection of commercially available 
moxifloxacin eye drops after IOL implantation(14). 
Despite these favorable results, some researchers believe that 
other factors may explain the decreased rate of endophthalmitis over 
time, including increased asepsis and antisepsis concerns, improve-
ment in surgical time and techniques, equipment evolution, changes 
in post-operative routines, or other unknown factors(17). Considering 
Table 1. Patient sex and age profile (n=3,751)
Parameter Group A Group B Total
Age (years) 68.1 ± 8.92 67.7 ± 9.03 67.8 ± 8.96
Female (%) 54.4 53.5 53.8
Male (%) 45.6 46.6 46.2
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this, the adoption of IC antibiotics may be only one of many measures 
that may reduce infection. As such, all possible precautions should be 
taken to reduce the possibility of endophthalmitis.
Another claim is that the low incidence of endophthalmitis does 
not justify antibiotic prophylaxis. Studies performed in the last de-
cade have demonstrated rates of endophthalmitis as low as 0.05% 
without the introduction of intracameral antibiotics(18,19). With such a 
low incidence, even if IC antibiotics reduced the risk 5-fold, it would 
be necessary to treat 2,500 patients to prevent one event of endo-
phthalmitis; this raises concerns about costs.
Our study did not account for the costs involved in the prophylac-
tic procedure or the treatment of endophthalmitis; nevertheless, 
previous studies have demonstrated prophylaxis with IC injections 
to be cost effective(8,14). 
Limitations of this study include its retrospective design as well as 
the lack of microbiological confirmation of endophthalmitis. To our 
knowledge, this is the first study in Brazil to evaluate infection rates 
and the incidence of complications after IC injection of commercially 
available moxifloxacin eye drop administration.
Although these results align with previous literature and may 
therefore be considered a clear argument for the routine use of 
moxifloxacin in cataract surgery, it is important to emphasize the 
fact that in Brazil, as in many other countries, there are no commer-
cially avai lable IC antibiotic solutions. The decision regarding use of 
self-prepared or commercially available eye drops for IC injection is 
left to the surgeon’s discretion and is considered off-label. 
We believe that approved antibiotic preparations for IC injection 
should increase the safety of cataract surgery by reducing the risk of 
endophthalmitis and dilution toxicity.
REFERENCES
 1.  Hughes D, Hill R. Infectious endophthalmitis after cataract surgery. Br J Ophthalmol. 
1994;78(3):227-32. Comment in: Br J Ophthalmol. 1994;78(12):948-9.
 2.  Chang DF, Braga-Mele R, Henderson BA, Mamalis N, Vasavada A; ASCRS Cataract 
Clinical Committee. Antibiotic prophylaxis of postoperative endophthalmitis after 
cataract surgery: results of the 2014 ASCRS member survey. J Cataract Refract Surg. 
2015;41(6):1300-5. 
 3.  Packer M, Chang DF, Dewey SH, Little BC, Mamalis N, Oetting TA, et al. Prevention, 
diagnosis, and management of acute postoperative bacterial endophthalmitis. J Ca-
ta ract Refract Surg. 2011;37(9):1699-714. 
 4.  Melo GB, Bispo PJ, Regatieri CV, Yu MC, Pignatari AC, Höfling-Lima AL. Incidence of 
endophthalmitis after cataract surgery (2002-2008) at a Brazilian university-hospital. 
Arq Bras Oftalmol. 2010;73(6):505-7. 
 5. Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract 
surgery: an evidence-based update. Ophthalmology. 2002;109(1):13-24. Comment 
in: Ophthalmology. 2003;110(8):1667; author reply 1667-8.
 6.  Schmitz S, Dick HB, Krummenauer F, Pfeiffer N. Endophthalmitis in cataract surgery: 
results of a German survey. Ophthalmology. 1999;106(10):1869-77. 
 7.  Endophthalmitis Study Group; European Society of Cataract & Refractive Surgeons. 
Prophylaxis of postoperative endophthalmitis following cataract surgery: results of 
the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg. 
2007;33(6):978-88. Comment in: J Cataract Refract Surg. 2008;34(1):9-10.
 8.  Linertová R, Abreu-González R, García-Pérez L, Alonso-Plasencia M, Cordovés-Dorta 
LM, Abreu-Reyes JA, et al. Intracameral cefuroxime and moxifloxacin used as endo-
phthalmitis prophylaxis after cataract surgery : systematic review of effectiveness and 
cost-effectiveness. Clin Ophthalmol. 2014;8:1515-22. 
 9.  Galvis V, Tello A, Sánchez MA, Camarcho PA. Cohort study of intracameral moxifloxa-
cin in postoperative endophthalmitis prophylaxis. Ophthalmol Eye Dis. 2014;6:1-14. 
 10.  Haruki T, Miyazaki D, Matsuura K, Terasaka Y, Noguchi Y, Inoue Y, et al. Comparison of 
toxicities of moxifloxacin, cefuroxime, and levofloxacin to corneal endothelial cells 
in vitro. J Cataract Refract Surg. 2014;40(11):1872-8. 
 11.  Matsuura K, Miyoshi T, Suto C, Akura J, Inoue Y. Efficacy and safety of prophylactic in-
tracameral moxifloxacin injection in Japan. J Cataract Refract Surg 2013;39(11):1702-6. 
 12.  Arbisser LB. Safety of intracameral moxifloxacin for prophylaxis of endophthalmitis 
after cataract surgery. J Cataract Refract Surg. 2008;34(7):1114-20. 
13.  O’Brien TP, Arshinoff SA, Mah FS. Perspectives on antibiotics for postoperative en-
dophthalmitis prophylaxis: potential role of moxifloxacin. J Cataract Refract Surg 2007; 
33(10):1790-800. 
 14.  Haripriya A, Chang DF, Namburar S, Smita A, Ravindran RD. Efficacy of intracameral 
moxifloxacin endophthalmitis prophylaxis at aravind eye hospital. Ophthalmology. 
2015;123(2):302-8. 
 15.  Qureshi F, Clark D. Macular infarction after inadvertent intracameral cefuroxime. J 
Ca taract Refract Surg. 2011;37(6):1168-9. 
 16.  Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroqui-
nolones: New weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 
2002;133(4):463-6. 
 17.  Schwartz SG, Flynn HW, Grzybowski A, Relhan N, Ferris FL 3rd. Intracameral Antibiotics 
and Cataract Surgery: Endophthalmitis Rates, Costs, and Stewardship. Ophthalmo-
logy. 2016;123(7):1411-3. 
 18.  Lalitha P, Rajagopalan J, Prakash K, Ramasamy K, Prajna NV, Srinivasan M. Postcataract 
endophthalmitis in South India: Incidence and outcome. Ophthalmology. 2005; 
112(11):1885-90. 
 19.  Moshirfar M, Feiz V, Vitale AT, Wegelin JA, Basavanthappa S, Wolsey DH. Endoph thal mitis 
after uncomplicated cataract surgery with the use of fourth-genera tion fluo roquinolones. 
A retrospective observational case series. Ophthalmology. 2007; 114(4):686-91. Com-
ment in: Ophthalmology. 2008;115(2):413-4; author reply 414. 
Simpósio Internacional do  
Banco de Olhos de Sorocaba
26 a 28 de outubro de 2017
Hospital Oftalmológico de Sorocaba
Informações: 
Tels.: (15) 3212-7838 / 7077
E-mail: simbos@bos.org.br 
